Safe administration of subsequent mRNA COVID-19 vaccine doses following a possible allergic reaction to the first dose

J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e880-e883. doi: 10.1111/jdv.18387. Epub 2022 Jul 12.

Authors

M S Roth^{1

2}, S Chantraine¹, C A Morales Mateluna¹, K Hartmann^#^{1

3}, C T Berger^#^{1

3

4}

Affiliations

¹ Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
² Division of Allergy, University Children's Hospital of Basel, Basel, Switzerland.
³ Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
⁴ University Center for Immunology, University Hospital Basel, Basel, Switzerland.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Hypersensitivity*
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger